Comparing four different ALK antibodies with manual immunohistochemistry (IHC) to screen for ALK-rearranged non-small cell lung cancer (NSCLC)

摘要: Abstract Objectives Anaplastic lymphoma kinase ( ALK )-rearranged non-small cell lung cancer (NSCLC) screening is essential to its treatment such as crizotinib. Different assays have been developed detect rearrangements, fluorescence in situ hybridization (FISH), reverse transcriptase-PCR (RT-PCR), and immunohistochemistry (IHC). However, detection has not applied widely all hospitals. Moreover, IHC proposed be a pre-screening tool because of wide application clinics. Since the low expression protein, sensitivity specificity antibody are keys success screening. Therefore, we compared different antibodies find best one for detection. Materials methods We evaluated by four antibodies: clone D5F3 (Ventana), (CST), 1A4/1H7 (OriGene Tech.), 5A4 (Abcam) based on manual cohort 60 NSCLCs. The results were with those from automated (clone D5F3, Ventana). All cases independently FISH. Results 32 ALK-positive 28 ALK-negative NSCLCs identified (D5F3, Ventana) FISH analysis. Based conventional IHC, antibodies—D5F3 (Abcam)—was 93.8%, 84.4%, 56.3%, respectively. Their specificities positive predictive values 100%. percentage strong-moderate staining was 65.6%, 62.5%, 68.8%, 21.9%, Compared Ventana), each concordance 96.7%, 91.7%, 76.7%, respectively, presented heterogeneity (weak–moderate–strong intensity). Conclusion These data indicated that more reliable might provide an effective strategy gene rearrangements NSCLC patients, followed confirmatory analysis IHC-positive cases.